Frankfurt - Delayed Quote EUR

Gubra A/S (PI3.F)

51.90

-0.15

(-0.29%)

At close: May 30 at 8:06:36 AM GMT+2

Trading Statement Q1-2025: A Landmark Deal for GUBamy

HØRSHOLM, DK / ACCESS Newswire / May 9, 2025 / Gubra (CPH:GUBRA) - Today, Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). ...

ACCESS Newswire 22 days ago

GUBRF
Gubra Welcomes New Board Members at 2025 AGM

HØRSHOLM, DK / ACCESS Newswire / April 3, 2025 / Gubra (CPH:GUBRA) Following Gubra's Annual General Meeting 2025 taking place earlier today we are pleased to confirm some exciting changes to the Board welcoming new perspectives to support the journey ...

ACCESS Newswire last month

GUBRF
Course of Gubra A/S' Annual General Meeting 2025

HØRSHOLM, DK / ACCESS Newswire / April 3, 2025 / Gubra (CPH:GUBRA) On Thursday, 3 April 2025 at 10:00 am (CEST), the annual general meeting of Gubra A/S (the "Company") was held at the Company's registered address Hørsholm Kongevej 11B, DK-2970 Hørsholm, ...

ACCESS Newswire last month

GUBRF
Successful Transaction Closure of License Agreement

HØRSHOLM, DK / ACCESS Newswire / April 1, 2025 / Gubra (CPH:GUBRA): With reference to Gubra's A/S (CPSE:GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for a license agreement to develop GUB014295, a potential ...

ACCESS Newswire last month

GUBRF
Gubra Announces Positive GUBamy Phase 1 Interim MAD Results

HØRSHOLM, DK / ACCESS Newswire / April 1, 2025 / Gubra (CPH:GUBRA) GUBamy was well tolerated with adverse events being predominantly GI related, mild and consistent with data from the SAD study. Doses of 1 mg and 2 mg GUBamy administered once-weekly ...

ACCESS Newswire last month

GUBRF
Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra

HØRSHOLM, DK / ACCESS Newswire / March 28, 2025 / Gubra (CPH:GUBRA) With reference to AbbVie's (NYSE:ABBV) and Gubra A/S' (CPSE:GUBRA) joint announcement of March 3, 2025 regarding a license agreement to develop GUB014295, a potential best-in-class, ...

ACCESS Newswire 2 months ago

GUBRF
Notice to Convene Annual General Meeting 2025

HØRSHOLM, DK / ACCESS Newswire / March 10, 2025 / Gubra (CPH:GUBRA) Notice to convene ANNUAL GENERAL MEETING 2025 GUBRA A/SCVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), notice is hereby given of the annual general meeting ...

ACCESS Newswire 2 months ago

GUBRF
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

HØRSHOLM, DK / ACCESS Newswire / March 03, 2025 / Gubra (CPH:GUBRA) Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's ...

ACCESS Newswire 2 months ago

GUBRF

Performance Overview

Return	PI3.F	OMX Copenhagen 25 Index (^OMXC25)
YTD	-37.62%	-0.88%
1-Year	+19.59%	-10.55%
3-Year	+257.93%	+3.45%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Gubra A/S (PI3.F)

Trading Statement Q1-2025: A Landmark Deal for GUBamy

Gubra Welcomes New Board Members at 2025 AGM

Course of Gubra A/S' Annual General Meeting 2025

Successful Transaction Closure of License Agreement

Gubra Announces Positive GUBamy Phase 1 Interim MAD Results

Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra

Notice to Convene Annual General Meeting 2025

AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

Performance Overview